Last10K.com

Trillium Therapeutics Inc. (TRIL) SEC Filing 6-K Foreign Issuer report for the period ending Tuesday, October 8, 2019

Trillium Therapeutics Inc.

CIK: 1616212 Ticker: TRIL

View differences made from one to another to evaluate Trillium Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Trillium Therapeutics Inc..

Continue

Assess how Trillium Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Trillium Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Material Contracts, Statements, Certifications & more

Trillium Therapeutics Inc. provided additional information to their SEC Filing as exhibits

Ticker: TRIL
CIK: 1616212
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001062993-19-003841
Submitted to the SEC: Tue Oct 08 2019 7:01:26 AM EST
Accepted by the SEC: Tue Oct 08 2019
Period: Tuesday, October 8, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/tril/0001062993-19-003841.htm